Resilient Bayer stock holds above EUR 48 as Kerendia trial data and REVEAL study update highlight pipeline strength
Published on 08/30/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer AG (ISIN DE000BAY0017) stock is trading in the high EUR 48 range as of August 28, 2026, with the latest Xetra close reported at EUR 48.67 and a year-to-date gain above 31 percent, reflecting renewed confidence in the company’s pharmaceuticals pipeline.
On August 30, 2026, new clinical data on the kidney and heart drug Kerendia and detailed results from the Phase III REVEAL study with the investigational PET radiotracer iodine 124 evuzamitide underscored Bayer’s focus on cardio-renal and imaging innovations, providing a fresh fundamental narrative for long-term investors.
Kerendia data extend cardio-renal profile
Recent reporting on August 30, 2026 highlighted that Kerendia, a drug developed by Bayer for the treatment of heart and kidney conditions, also shows efficacy in patients suffering from hypertensive nephropathy, widening the potential patient population for the therapy.
The same overview of Bayer’s stock performance linked this clinical update with a closing share price of EUR 48.67 on Xetra on August 28, 2026 and a one-week change of 0.39 percent, suggesting that the market has been digesting the news with a modest positive bias rather than a sharp re-pricing.
Pipeline update from Phase III REVEAL study
In a corporate news release dated August 30, 2026, Bayer announced first detailed results from the Phase III REVEAL study, an investigator-initiated trial by Brigham and Women’s Hospital evaluating the investigational positron emission tomography radiotracer iodine 124 evuzamitide.
According to the announcement, the REVEAL study is designed to provide imaging insights that could improve the diagnosis and management of cardiovascular conditions, adding another potential pillar to Bayer’s late-stage pipeline alongside established cardio-renal products such as Kerendia.
The timing of the REVEAL data release, coinciding with presentation as a late-breaking contribution at ESC 2026, positions Bayer to showcase its innovation credentials to a broad cardiology audience and may support sentiment toward Bayer stock if follow-up data confirm robust imaging performance.
Market view, valuation context and consensus expectations
A recent market-data overview for Bayer shares on August 29, 2026 showed the Tradegate quote at EUR 48.76, representing a daily gain of 0.64 percent and a year-to-date increase of 31.82 percent, which places the current price in the upper part of the stock’s 2026 trading range.
That same overview cited an average published price target of EUR 57.39 for Bayer shares compared with the latest close of EUR 48.67, implying upside of 17.91 percent if the consensus scenario on earnings and pipeline execution is achieved.
For investors, the numerical spread between the current price level and the average price target quantifies the degree to which analysts have factored in successful delivery on late-stage programs such as Kerendia label extensions and imaging assets like iodine 124 evuzamitide.
The recent clinical and pipeline news appears in a context where Bayer has been working to strengthen its balance between its pharmaceuticals segment and its crop science business, and the market data suggest that the equity market is rewarding visible progress with a double-digit year-to-date performance.
Representative product: Kerendia in hypertensive nephropathy
Kerendia is a drug from Bayer’s cardiovascular and renal portfolio used to treat patients with heart and kidney disease, and the August 30, 2026 clinical update indicated that the therapy also delivers efficacy for patients with hypertensive nephropathy, a form of kidney damage arising from high blood pressure.
By demonstrating clinical benefit in hypertensive nephropathy in addition to other cardio-renal indications, Kerendia’s potential market reaches beyond patients with diabetic nephropathy or more narrowly defined kidney conditions, thereby increasing the strategic importance of this product in Bayer’s pharmaceutical lineup.
Bayer stock level and trading venue context
As of the Xetra close on August 28, 2026, Bayer stock traded at EUR 48.67, and a Tradegate quote on August 29, 2026 showed EUR 48.76, underscoring that the shares are holding just under the EUR 50 mark in recent sessions.
With the stock listed in Germany and actively traded on venues such as Xetra and Tradegate, Bayer’s shares remain an important European large-cap exposure, and the combination of a more than 31 percent year-to-date gain and a consensus price target premium of 17.91 percent defines the current market-implied risk-reward profile for the name.
Fact box
Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra
Price (as of August 28, 2026, Xetra close): EUR 48.67
Sector / Industry: Health care / Pharmaceuticals and crop science
Index membership: DAX
